Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.
Sunnåker M, Bhattacharya C, Nelander K, Aurell M, Heijer M, Collén A, Han D, Holden J, Trebski M, Garkaviy P, Ericsson H. Sunnåker M, et al. Among authors: nelander k. Clin Drug Investig. 2024 Nov;44(11):863-874. doi: 10.1007/s40261-024-01402-x. Epub 2024 Nov 4. Clin Drug Investig. 2024. PMID: 39495467 Free PMC article. Clinical Trial.
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Knöchel J, Nelander K, Heijer M, Lindstedt EL, Forsberg GB, Whatling C, Shimada H, Han DS, Gabrielsen A, Garkaviy P, Ericsson H. Knöchel J, et al. Among authors: nelander k. Clin Drug Investig. 2021 Oct;41(10):895-905. doi: 10.1007/s40261-021-01078-7. Epub 2021 Sep 21. Clin Drug Investig. 2021. PMID: 34546534 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Gan LM, Lagerström-Fermér M, Ericsson H, Nelander K, Lindstedt EL, Michaëlsson E, Kjaer M, Heijer M, Whatling C, Fuhr R. Gan LM, et al. Among authors: nelander k. Br J Clin Pharmacol. 2019 Apr;85(4):762-770. doi: 10.1111/bcp.13855. Epub 2019 Feb 18. Br J Clin Pharmacol. 2019. PMID: 30618054 Free PMC article. Clinical Trial.
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.
Ericsson H, Nelander K, Heijer M, Kjaer M, Lindstedt EL, Albayaty M, Forte P, Lagerström-Fermér M, Skrtic S. Ericsson H, et al. Among authors: nelander k. Clin Pharmacol Drug Dev. 2020 Apr;9(3):411-421. doi: 10.1002/cpdd.756. Epub 2019 Dec 2. Clin Pharmacol Drug Dev. 2020. PMID: 31793171 Free PMC article. Clinical Trial.
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Nelander K, Lagerstrom-Fermer M, Amilon C, Michaëlsson E, Heijer M, Kjaer M, Russell M, Han D, Lindstedt EL, Whatling C, Gan LM, Ericsson H. Nelander K, et al. Clin Transl Sci. 2021 May;14(3):812-819. doi: 10.1111/cts.12859. Epub 2021 May 2. Clin Transl Sci. 2021. PMID: 32770730 Free PMC article. Clinical Trial.
Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.
Lund LH, Lam CSP, Pizzato PE, Gabrielsen A, Michaëlsson E, Nelander K, Ericsson H, Holden J, Folkvaljon F, Mattsson A, Collén A, Aurell M, Whatling C, Baldus S, Drelich G, Goudev A, Merkely B, Bergh N, Shah SJ. Lund LH, et al. Among authors: nelander k. Eur J Heart Fail. 2023 Sep;25(9):1696-1707. doi: 10.1002/ejhf.2977. Epub 2023 Aug 22. Eur J Heart Fail. 2023. PMID: 37470101 Free PMC article. Clinical Trial.
A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.
Knöchel J, Panduga V, Nelander K, Heijer M, Lindstedt EL, Ali H, Aurell M, Ödesjö H, Forte P, Connolly K, Ericsson H, MacPhee I. Knöchel J, et al. Among authors: nelander k. Br J Clin Pharmacol. 2024 Sep;90(9):2180-2187. doi: 10.1111/bcp.16131. Epub 2024 Jun 3. Br J Clin Pharmacol. 2024. PMID: 38830622 Clinical Trial.
Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.
Li XQ, Lindmark B, Amilon C, Samuelsson K, Weidolf L, Nelander K, Knöchel J, Heijer M, Bragg RA, Gränfors M, Lindstedt EL, Sidhu S, Garkaviy P, Ericsson H. Li XQ, et al. Among authors: nelander k. Pharmacol Res Perspect. 2024 Oct;12(5):e70029. doi: 10.1002/prp2.70029. Pharmacol Res Perspect. 2024. PMID: 39400479 Free PMC article.
22 results